Cytosorbents Corporation (CTSO)
1.00
0.00 (0.00%)
At close: Mar 31, 2025, 12:36 PM
Cytosorbents Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 | FY07 | FY06 | FY05 |
| Revenue | 36.35M | 29.36M | 40.11M | 39.45M | 22.77M | 20.25M | 13.38M | 8.21M | 4.06M | 3.15M | 821.79K | 151.57K | 36.08K | n/a | n/a | n/a | n/a | n/a | 10K |
| Cost of Revenue | 13.96M | 13.96M | 11.05M | 11.05M | 7.36M | 7.49M | 5.52M | 3.95M | 2.21M | 2.13M | 1.91M | 319.3K | 11.76K | n/a | n/a | n/a | n/a | n/a | 10K |
| Gross Profit | 22.39M | 15.4M | 29.06M | 28.4M | 15.4M | 12.76M | 7.86M | 4.25M | 1.84M | 1.01M | -1.09M | -167.72K | 24.32K | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Income | -31.21M | -31.52M | -22.75M | -10.37M | -18.97M | -15.58M | -9.84M | -11.49M | -9.3M | -7.28M | -4.71M | -3.49M | -4.44M | -2.82M | -2.43M | -3.24M | -3.07M | -2.96M | -80K |
| Interest Income | n/a | 133K | 28K | 1.2M | 1.03M | n/a | n/a | n/a | 18.6K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 67.36K | n/a | n/a |
| Pretax Income | -29.32M | -33.91M | -25.3M | -8.96M | -20.36M | -17.83M | -9.14M | -12.26M | -8.46M | -9.71M | -5.14M | -4.06M | -5.48M | 2.91M | 3.04M | -3.27M | -3.35M | -7.67M | -80K |
| Net Income | -28.51M | -32.81M | -24.56M | -7.84M | -19.27M | -17.21M | -8.46M | -11.94M | -8.13M | -9.32M | -4.68M | -3.66M | -5.48M | -2.91M | -2.74M | -3.02M | -3.35M | -7.67M | -80K |
| Selling & General & Admin | 36.94M | 37.14M | 38.48M | 31.51M | 24.47M | 22.88M | 15.43M | 12.28M | 8.01M | 6.84M | 3.49M | 1.98M | 1.57M | 1.07M | 1.07M | 1.26M | 1.65M | 1.85M | 70K |
| Research & Development | 15.73M | 15.12M | 16.38M | 8.81M | 12.09M | 7.72M | 4.05M | 4.78M | 3.87M | 2.43M | 1.74M | 2.53M | 2.89M | 1.76M | 1.96M | 1.98M | 1.42M | 1.11M | n/a |
| Other Expenses | 936K | -5.33M | -3.06M | -1.55M | -2.18M | -2.25M | -1.77M | -1.32M | -735.86K | -2.43M | -1.6M | -1.19M | n/a | n/a | n/a | n/a | n/a | n/a | 10K |
| Operating Expenses | 53.6M | 46.93M | 51.81M | 38.77M | 34.38M | 28.35M | 17.71M | 15.74M | 11.15M | 8.29M | 3.62M | 3.32M | 4.46M | 2.82M | 3.03M | 3.24M | 3.07M | 2.96M | 80K |
| Interest Expense | 157.89K | 132.6K | n/a | 1.2M | 1.03M | 1.46M | 749.08K | 231.8K | 9.3K | 310.02K | 422.84K | 564.43K | 1.04M | 84.85K | 8.14K | 22.21K | -3.35M | 4.74M | n/a |
| Selling & Marketing Expenses | -936K | 582K | 615K | 285K | 314K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 307.95K | 351.36K | n/a | 912.38K | n/a |
| Cost & Expenses | 67.56M | 60.88M | 62.85M | 49.82M | 41.74M | 35.84M | 23.22M | 19.7M | 13.36M | 10.42M | 5.54M | 3.64M | 4.47M | 2.82M | 3.03M | 3.24M | 3.07M | 2.96M | 90K |
| Income Tax | -813.74K | -1.09M | -736K | -1.13M | -1.09M | -619.55K | -676.74K | -318.55K | -324.61K | -386K | -458.28K | -391.76K | 1.04M | 5.82M | 298.79K | -248.53K | 3.35M | 7.67M | n/a |
| Shares Outstanding (Basic) | 44.66M | 43.57M | 43.36M | 38.82M | 32.26M | 30.72M | 27.61M | 25.43M | 24.89M | 14.38M | 9.44M | 7.93M | 6.41M | 3.92M | 1.66M | 1M | 993.94K | 598.24K | 310K |
| Shares Outstanding (Diluted) | 44.66M | 43.57M | 43.36M | 38.82M | 32.26M | 30.72M | 27.61M | 25.43M | 24.89M | 14.38M | 9.44M | 7.93M | 6.41M | 3.92M | 1.66M | 1M | 993.94K | 598.24K | 310K |
| EPS (Basic) | -0.64 | -0.75 | -0.57 | -0.2 | -0.6 | -0.56 | -0.31 | -0.47 | -0.33 | -0.65 | -0.5 | -0.46 | -0.86 | -0.74 | -1.64 | -3 | -3.37 | -12.82 | -0.26 |
| EPS (Diluted) | -0.64 | -0.75 | -0.57 | -0.2 | -0.6 | -0.56 | -0.31 | -0.47 | -0.33 | -0.65 | -0.5 | -0.46 | -0.86 | -0.74 | -1.64 | -3 | -3.37 | -12.82 | -0.26 |
| EBITDA | -29.18M | -30M | -22.01M | -9.71M | -18.74M | -15.98M | -8.17M | -11.86M | -9.19M | -6.83M | -4.65M | -3.44M | -4.4M | -2.81M | -2.98M | -3.14M | -3.16M | -1.74M | -70K |
| Depreciation & Amortization | 2.03M | 1.13M | 1.13M | 660.79K | 581.53K | 390.55K | 218.27K | 161.61K | 112.97K | 65.55K | 64.35K | 54.61K | 39.15K | 17.8K | 51.7K | 103.7K | 190.44K | 1.26M | 10K |